| Literature DB >> 31686030 |
Luz S Gonzalez-Delgado1,2, Hannah Walters-Morgan3, Bartłomiej Salamaga1,2, Angus J Robertson1,2, Andrea M Hounslow1,2, Elżbieta Jagielska4, Izabela Sabała4, Mike P Williamson5,6, Andrew L Lovering7, Stéphane Mesnage8,9.
Abstract
Lysostaphin is a bacteriolytic enzyme targeting peptidoglycan, the essential component of the bacterial cell envelope. It displays a very potent and specific activity toward staphylococci, includingEntities:
Mesh:
Substances:
Year: 2019 PMID: 31686030 PMCID: PMC6920042 DOI: 10.1038/s41589-019-0393-4
Source DB: PubMed Journal: Nat Chem Biol ISSN: 1552-4450 Impact factor: 15.040
Figure 1Mapping the interaction surface of the SH3b domain with synthetic S. aureus PG fragments
For each NMR titration, the average CSP was calculated and two-fold average CSP was chosen as a threshold to identify surface residues interacting with ligands. The residues interacting with the pentaglycine crossbridges are highlighted in red, those interacting with the peptide stem in green. Interaction maps corresponding to six ligands are shown. a, G5 peptide; b, P4; c, P4-G5; d, P5-G5-P4; f, GM-P5-G5-GM-P4-G5. Titrations confirmed the existence of a narrow cleft previously proposed to bind the PG crossbridges [19] and recently shown to interact with pentaglycine [20]. They also revealed a set of residues interacting with the peptide stem, located on the face of the protein opposite to the G5 binding cleft.
Figure 2Structure of lysostaphin SH3b in complex with the P4-G5 ligand
The SH3b domain and a symmetry-related partner are coloured white and blue, respectively; ligand is coloured by atom type, with P4 C atoms green and G5 C atoms pink. a, protein fold with termini labelled, and two representations (fold and ligand in ribbon/stick and surface formats). b, Co-crystal structure showing the SH3b:ligand shape complementarity. c, Rotated view of a single SH3b domain showing the interaction with the P4 ligand (blue, with peptide units labelled 1-4). d, experimental 2Fo-Fc difference map contoured at 1 σ for different regions of the bound ligand, with selected interacting residues in stick form. The L-Ala 1 end panel is from the 2.5 Å dataset, others are from the 1.4 Å form. Residues from the symmetry-related SH3b domain are denoted by use of a prime (‘), and hydrogen bonds represented as a dashed line.
Figure 3Binding activity of recombinant SH3b-mNeonGreen (SH3b-NG) proteins to purified S. aureus peptidoglycan
a, peptidogycan binding activities of WT SH3b-NG on S. aureus WT and fem mutants with an altered peptidoglycan crossbridge. b, peptidogycan binding activities of WT SH3b-NG and derivatives with mutations in residues involved in the interaction with the G5 ligand. c, peptidoglycan binding activities of WT SH3b-NG and derivatives with mutations in residues involved in the interaction with the P4 ligand. The graphs show dose-binding responses whilst Supplementary Table 2 indicates the amount of PG required for 50% binding (PG50) and the corresponding fold change compared to the amount of PG required for 50% binding of the WT protein as a reference.
Figure 4Models for binding of a ligand at two sites
a, schematic representation of a receptor with two sites (R1 and R2), which bind the L1 and L2 ligand sites respectively. L1 and L2 are connected by a flexible linker. b, the flexibility of the linker allows the R1 site to stay attached, but the R2 site to detach. The effective concentration of L2 at the R2 site (and thus the cooperativity of binding) will depend on the length and flexibility of the linker. c, if the linker is too short, it is not possible for the ligand to bind simultaneously at both R1 and R2. It can alternate between both sites, which will still result in cooperative binding, though less than in case b. d, a weaker enthalpy of binding (for example due to the shortness of the linker preventing optimal binding at both sites) can to some extent be compensated by greater entropy (increased relative motion of ligand and receptor) if there is weak binding in non-optimal positions.